comparemela.com

Srikala Sridhar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Long-term Outcomes From JAVELIN Bladder 100 Solidify Maintenance Avelumab as SOC in Metastatic Urothelial Carcinoma

A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.

Merck: New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.